5-Amino-1MQ Bloodwork: 8 Labs to Track (2026)
Most people track weight and energy — but the lab that actually shows if 5-amino-1MQ is working gets overlooked by 90% of users. HOMA-IR reveals metabolic improvements weeks before the scale budges, making it your early success indicator.
5-Amino-1MQ works by inhibiting NNMT (nicotinamide N-methyltransferase), which preserves cellular NAD+ and improves metabolic function. Unlike appetite suppressants, its benefits show up in bloodwork before becoming visible, making lab monitoring essential for tracking progress.
Research-context information only. 5-Amino-1MQ is an investigational research compound not approved by any regulatory body. Protocols, doses, and reactions reported below come from published clinical trials and self-reported community sources. This article reports what has been documented, not what should be done. Possession or use of investigational drugs outside an authorized clinical trial may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
Baseline Labs: Pre-Treatment Assessment
Before starting 5-amino-1MQ, establish baseline values for safety and efficacy tracking. These labs create your personal reference point and help identify contraindications.
Essential Pre-Treatment Panel:
- Comprehensive Metabolic Panel (liver and kidney function)
- Lipid panel (cholesterol, triglycerides)
- Fasting insulin and glucose
- HbA1c (3-month glucose average)
Safety Screening:
- Complete Blood Count (CBC)
- Thyroid function (TSH, free T3/T4)
- Inflammatory markers (if indicated)
Schedule baseline labs 1-2 weeks before starting treatment to ensure accurate pre-treatment values.
Lab #1: Lipid Panel — The Metabolic Foundation
Why It Matters: NNMT inhibition directly affects lipid metabolism by preserving NAD+ cofactors essential for fat oxidation. Research consistently shows improvements in cholesterol and triglycerides with effective NNMT inhibition.
Key Markers:
- Triglycerides: Most sensitive to NNMT inhibition
- LDL cholesterol: Often decreases with metabolic improvement
- HDL cholesterol: May increase as metabolism improves
Testing Schedule: Baseline, 8 weeks, 16 weeks
Studies show triglycerides are among the first lipid markers to improve with NNMT inhibition. A 2024 study found "decreased circulating cholesterol levels" in mice treated with NNMT inhibitors, with triglycerides showing the most dramatic improvement.
Lab #2: Fasting Insulin — Insulin Sensitivity Marker
Why It Matters: This is the lab most people skip — and the one that reveals if 5-amino-1MQ is working at the cellular level. Fasting insulin improvements often appear 4-6 weeks before noticeable weight loss.
Optimal Range: 2-5 µIU/mL (anything above 10 suggests insulin resistance)
What Research Shows: Studies consistently demonstrate that NNMT inhibition "enhances insulin sensitivity" through NAD+-dependent metabolic pathways. This improvement is measurable weeks before body composition changes.
Testing Schedule: Baseline, 4 weeks, 8 weeks, 12 weeks
Clinical Insight: If fasting insulin isn't improving by week 6-8, consider dose optimization or assess for interfering factors (stress, sleep, diet quality).
Lab #3: HbA1c — Glucose Metabolism
Why It Matters: HbA1c reflects 2-3 months of glucose control, making it ideal for tracking longer-term metabolic improvements from NNMT inhibition. It's less sensitive to daily fluctuations than fasting glucose.
Optimal Range: < 5.0% (5.0-5.4% is acceptable, 5.7%+ indicates problems)
NNMT Connection: Research shows NNMT knockout animals have "markedly enhanced fasting blood glucose levels, glucose tolerance, and insulin sensitivity." 5-amino-1MQ mimics these effects in humans.
Testing Schedule: Baseline, 12 weeks, 24 weeks (due to 3-month reflection period)
Interpretation: HbA1c improvements typically lag behind fasting insulin changes by 6-8 weeks due to the longer reflection period of this marker.
Lab #4: Liver Enzymes (ALT) — Safety Monitoring
Why It Matters: Liver enzymes are critical safety markers for any compound affecting metabolism. While 5-amino-1MQ research shows liver benefits, individual monitoring remains essential.
Key Markers:
- ALT (Alanine Aminotransferase): Most sensitive liver marker
- AST (Aspartate Aminotransferase): Secondary liver indicator
Safety Thresholds:
- ALT > 3x upper normal limit = stop immediately
- ALT > 2x upper normal = reduce dose and retest in 1 week
- Gradual ALT increase = monitor closely
Research Context: Studies actually show liver improvements with NNMT inhibition. Research indicates NNMT produces 1-MNA, which "promotes hepatotoxicity and abnormal TG storage in the liver." Blocking this pathway may improve liver function.
Ready to buy? Compare verified vendors on our best 5-amino-1MQ sources page, or browse all coupon codes for up to 50% off.
